David Griffin

Oncology

380 Serpentine Dr Ste 200A
Spartanburg, SC 29303

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2 publications

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

Journal: Gynecologic oncology

Published: May 27, 2015

Letter to the editor.

Letter to the editor.

Journal: Journal of veterinary internal medicine

Published: July 16, 2013

Showing 1-2 of 2

Last Updated: 09/26/2026